Form 4: VolitionRx Chief Medical Officer Andrew Retter Reports Acquisition of 100,000 Shares of Common Stock

Chief Medical Officer of VolitionRx, Andrew Retter, reports acquiring 100,000 shares of common stock as part of a restricted stock unit (RSU) grant.

Summary

• Andrew Retter, Chief Medical Officer of VolitionRx Ltd, filed a Form 4 on May 24, 2024, reporting a transaction on May 23, 2024.
• Retter acquired 100,000 shares of VolitionRx common stock through restricted stock units (RSUs).
• These RSUs are subject to a 3-year vesting schedule.
• The vesting schedule is as follows: 33,334 units on May 23, 2025, 33,333 units on May 23, 2026, and 33,333 units on May 23, 2027.
• Upon vesting and settlement, Retter will receive common stock equal to the number of vested RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive due to the incentive structure.

Positives

• The grant of RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the RSU vesting schedule.

Industry Context

Stock grants and RSU awards are common compensation practices for executives in publicly traded companies, aligning their interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation, used by companies like Exact Sciences (EXAS) and Guardant Health (GH) to attract and retain key personnel.
• Vesting schedules, such as the 3-year schedule outlined in the document, are typical in the industry to ensure long-term commitment.
• The size of the grant should be compared to similar grants at peer companies to assess its relative value and impact.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's interests with increasing shareholder value.
• Employees: The grant may have a positive impact on employee morale as it demonstrates investment in key personnel.

Key Dates